U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Eye Institute (NEI)
For Immediate Release: Friday, February 22, 2008
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Eye Institute (NEI) <http://www.nei.nih.gov/>
For Immediate Release: Friday, February 22, 2008
Contact: National Eye Institute, 301-496-5248, <e-mail: neinews@nei.nih.gov>
COMPARISON OF AMD TREATMENTS TRIALS (CATT): LUCENTIS -- AVASTIN TRIAL
The National Eye Institute (NEI) of the National Institutes of Health (NIH) announces the start of a multicenter clinical trial to compare the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration (AMD). The two drugs are Lucentis (ranibizumab) and Avastin (bevacizumab). AMD is a disease that damages the macula. The macula is the area of the retina responsible for central vision. AMD is a leading cause of blindness among older Americans. Nearly two million Americans are visually impaired by AMD, while more than seven million are at increased risk of vision loss from the disease.
"Visual impairment from AMD can lead to loss of independence and a reduced quality of life," said Paul A. Sieving, M.D., Ph.D., director of NEI. "This clinical trial will evaluate whether the treatment burden for patients can be reduced without compromising effectiveness."
Lucentis was approved by the U.S. Food and Drug Administration (FDA) in June of 2006 for the treatment of advanced, or wet, AMD. The approval was based on evidence from clinical trials showing that Lucentis slows the rate of progression of vision loss from wet AMD. In addition to a low rate of developing vision loss, approximately one-third of patients treated in these trials had some improvement in vision, as measured on an eye chart, at 12 months.
Avastin is a drug closely related to Lucentis. It was approved by the FDA in 2004 as an intravenous treatment for patients with advanced colorectal cancer and therefore has been available for what is called off-label use for other health conditions. It has been widely used off-label to treat wet AMD. Avastin is thought to remain in the eye longer than Lucentis and therefore possibly allow for less frequent injections.
Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula. These new blood vessels leak blood and fluid, damaging the macula and causing a rapid loss of vision. The growth of new blood vessels is called angiogenesis or neovascularization. NIH-supported research has helped establish that a protein called vascular endothelial growth factor (VEGF) is an important element in angiogenesis. This research provided a stimulus for the development of a number of anti-angiogenic or anti-VEGF drugs, including Lucentis and Avastin.
The Lucentis -- Avastin trial will determine the relative safety and effectiveness of treating wet AMD in 1,200 patients who will be treated with either:
-- Injection of Lucentis on a fixed schedule of once every four weeks for one year, with the patient being assigned randomly in the second year to either an injection of Lucentis every four weeks or on a variable schedule depending on the patient's response to treatment;
-- Injection of Avastin on a fixed schedule of once every four weeks for one year, with the patient being assigned randomly in the second year to either an injection of Avastin every four weeks or on a variable schedule depending on the patient's response to treatment;
-- Injection of Lucentis on a variable schedule;
-- Injection of Avastin on a variable schedule.
The primary outcome measure will be change in visual acuity. Secondary outcome measures will include number of treatments, anatomical changes in the retina, adverse events, and cost.
This clinical trial will be conducted at 47 clinical centers across the country. It is hoped the results of this study will improve the treatment of wet AMD. Reducing the frequency of treatments without compromising effectiveness would reduce the treatment burden for patients and produce a potential cost savings.
For a list of clinical centers, eligibility recruitments, and other information, go to: <http://www.nei.nih.gov/CATT>, or call the CATT Coordinating Center at 1-800-000-0000.
Lucentis and Avastin are products of Genentech, Inc.
The National Eye Institute (NEI) is part of the National Institutes of Health (NIH) and is the federal government's lead agency for vision research that leads to sight-saving treatments and plays a key role in reducing visual impairment and blindness. For more information, visit the NEI Website at <http://www.nei.nih.gov>.
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - is comprised of 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <www.nih.gov>.
Source: http://paxalles.blogs.com/paxalles/2008/02/comparison-of-a.html
Related blog articles:
ASUS M3A32-MVP Deluxe - AMD 790FX Mainboard Review
AMD Return Policy
AMD AM2 X2 BE-2350 45w CPU?
Related articles on the web:
...... a multicenter clinical trial to compare the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration (AMD). The two drugs are Lucentis (ranibizumab) and Avastin (bevacizumab). ...
http://uprm.info/grants/?p=383952
...*Phase II Clinical Trial of Bevacizumab for Adenocarcinoma of the Pancreas *CATT Study Update 3: Avastin vs. Lucentis — To Get Underway by Year’s End! Category:Angiogenesis inhibitors Category:Cancer treatments ...
http://buy-prescription-drugs-in-canada.infogleam.com/archives/2007/11/14/buy-generic-cialis-softtabs/
...Martin, delivered an update on funding for the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT ) Study. A recently revised Medicare policy will support the use of Lucentis in the trial, and patients will have no ...
http://irvaronsjournal.blogspot.com/2007/11/more-news-from-2007-aao-day-three.html
...The Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) is a set of multicenter, randomized clinical trials of treatments for neovascular age-related macular degeneration (AMD), the leading cause of blindness in the ...
http://irvaronsjournal.blogspot.com/2007/09/catt-study-update-3-avastin-vs-lucentis.html
...Martin, MD, a member of the session's panel, questioned Genentech's refusal to support the upcoming Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) trial, which is expected to evaluate both bevacizumab and ...
http://irvaronsjournal.blogspot.com/2007/11/retina-2007-subspecialty-meeting_11.html
...There is also an update on the NeoVista Strontium 90 clinical trial, the Two-Year results of the PRONTO Study, and a short piece on how walking and exercise can lead to a drop in the propensity to develop wet AMD. Avastin vs Lucentis ...
http://irvaronsjournal.blogspot.com/2007/10/menu-part-8-catt-more-on-avastin-vs.html
...This is true, but it’s pretty rich to hear that objection coming from Genentech, which has refused to cooperate with a head-to-head trial of Avastin and Lucentis [the CATT Study] planned by the National Eye Institute. ...
http://irvaronsjournal.blogspot.com/2007/10/avastinlucentis-update-18-genentech-yes.html
...The Lucentis-Avastin comparison trial is supported by the National Eye Institute (NEI) of the National Institute of Health (NIH). The study will enroll about 1200 patients with newly diagnosed AMD, randomly assigned to one of four ...
http://irvaronsjournal.blogspot.com/2007/09/catt-study-update-2-avastin-vs-lucentis.html
...Williams, MD explained how bevacizumab has greatly impacted age-related macular degeneration treatment, despite the fact that is has not gained US approval for treating the disease and the lack of clinical trial data to support its use. ...
http://irvaronsjournal.blogspot.com/2007/11/retina-2007-subspecialty-meeting.html
...A third AMD trial is the Complications of AMD Treatments Trial or CATT. This trial is being chaired by Dan Martin of Emory. It’s due to start in late spring. The study will compare monthly injections using Avastin to monthly injections ...
http://www.medrounds.org/amd/2007/01/catt-more-on-important-amd-trials.html
0 comments:
Post a Comment